Sanofi acquires 2.3% of its shares from long-standing shareholder L'Oréal Ruchika Sharma4 Feb 2025 1:06 PM ISTParis: Sanofi has announced the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s...
Sanofi Sarclisa approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Ruchika Sharma2 Feb 2025 10:45 AM ISTParis: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a...
Sanofi Sarclisa approved in EU for newly diagnosed multiple myeloma Ruchika Sharma26 Jan 2025 1:30 PM ISTParis: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Sanofi Sarclisa gains Chinese nod for treatment of adult patients with relapsed or refractory multiple myeloma Ruchika Sharma14 Jan 2025 1:30 PM ISTParis: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine,...
Sanofi appoints Jean-Paul Kress as Independent Director Ruchika Sharma21 Dec 2024 12:30 PM ISTParis: Sanofi has announced the appointment of Jean-Paul Kress as an Independent Director, effective January 1, 2025. Jean-Paul Kress will...
Sanofi gets USFDA Breakthrough Therapy designation for multiple sclerosis therapy Tolebrutinib Ruchika Sharma17 Dec 2024 11:32 AM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Tolebrutinib for the...
USFDA grants Breakthrough Therapy designation to Sanofi tolebrutinib for non-relapsing secondary progressive multiple sclerosis Ruchika Sharma13 Dec 2024 3:53 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib...
Two Sanofi combination vaccine candidates for prevention of influenza, COVID gets USFDA Fast Track designation Ruchika Sharma11 Dec 2024 12:25 PM ISTParis: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent...
Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria Ruchika Sharma17 Nov 2024 4:15 PM ISTParis: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the...
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly diagnosed multiple myeloma: Sanofi Ruchika Sharma17 Nov 2024 4:00 PM ISTParis: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted a...
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis Ruchika Sharma7 Nov 2024 3:55 PM ISTParis: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in...
Sanofi, Regeneron get USFDA nod for Dupixent for COPD Ruchika Sharma29 Sept 2024 12:30 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment...
